Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates

Chemistry and Biology

Volumn 20, Issue 2, 2013, Pages 161-167

  Strop, Pavel ^a   Liu, Shu Hui ^a   Dorywalska, Magdalena ^a   Delaria, Kathy ^a   Dushin, Russell G ^a   Tran, Thomas Toan ^a   Ho, Wei Hsien ^a   Farias, Santiago ^a   Casas, Meritxell Galindo ^a   Abdiche, Yasmina ^a   Zhou, Dahui ^a   Chandrasekaran, Ramalakshmi ^a   Samain, Caroline ^a   Loo, Carole ^a   Rossi, Andrea ^a   Rickert, Mathias ^a   Krimm, Stellanie ^a   Wong, Teresa ^a   Chin, Sherman Michael ^a   Yu, Jessica ^a   Dilley, Jeanette ^a   Chaparro Riggers, Javier ^a   Filzen, Gary F ^a   O'Donnell, Christopher J ^a   Wang, Fang ^a   Myers, Jeremy S ^a   Pons, Jaume ^a   Shelton, David L ^a   Rajpal, Arvind ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; CYSTEINE CONJUGATE; DRUG ANTIBODY; MALEIMIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG STABILITY; DRUG TOLERABILITY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RAT; STOICHIOMETRY; STREPTOVERTICILLIUM; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; NEOPLASMS; RATS; TRANSGLUTAMINASES; TUBULIN MODULATORS;

EID: 84874300889     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.01.010     Document Type: Article

References (20)

1. S.C. Alley, D.R. Benjamin, S.C. Jeffrey, N.M. Okeley, D.L. Meyer, R.J. Sanderson, and P.D. Senter Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjug. Chem. 19 2008 759 765
2. J.Y. Axup, K.M. Bajjuri, M. Ritland, B.M. Hutchins, C.H. Kim, S.A. Kazane, R. Halder, J.S. Forsyth, A.F. Santidrian, and K. Stafin Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. USA 109 2012 16101 16106
3. C. Chumsae, G. Gaza-Bulseco, and H. Liu Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry Anal. Chem. 81 2009 6449 6457
4. N. Gomez, J. Ouyang, M.D. Nguyen, A.R. Vinson, A.A. Lin, and I.H. Yuk Effect of temperature, pH, dissolved oxygen, and hydrolysate on the formation of triple light chain antibodies in cell culture Biotechnol. Prog. 26 2010 1438 1445
5. N. Gomez, A.R. Vinson, J. Ouyang, M.D. Nguyen, X.N. Chen, V.K. Sharma, and I.H. Yuk Triple light chain antibodies: factors that influence its formation in cell culture Biotechnol. Bioeng. 105 2010 748 760
6. K.J. Hamblett, P.D. Senter, D.F. Chace, M.M. Sun, J. Lenox, C.G. Cerveny, K.M. Kissler, S.X. Bernhardt, A.K. Kopcha, and R.F. Zabinski Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10 2004 7063 7070
7. S. Jeger, K. Zimmermann, A. Blanc, J. Grünberg, M. Honer, P. Hunziker, H. Struthers, and R. Schibli Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase Angew. Chem. Int. Ed. Engl. 49 2010 9995 9997
8. J.R. Junutula, H. Raab, S. Clark, S. Bhakta, D.D. Leipold, S. Weir, Y. Chen, M. Simpson, S.P. Tsai, and M.S. Dennis Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
9. J.R. Junutula, K.M. Flagella, R.A. Graham, K.L. Parsons, E. Ha, H. Raab, S. Bhakta, T. Nguyen, D.L. Dugger, and G. Li Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16 2010 4769 4778
10. J.M. Lambert Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 2012 10.1111/bcp.12044 Published online November 23, 2012
11. C.F. McDonagh, E. Turcott, L. Westendorf, J.B. Webster, S.C. Alley, K. Kim, J. Andreyka, I. Stone, K.J. Hamblett, J.A. Francisco, and P. Carter Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel. 19 2006 299 307
12. K. Miyazaki, M. Kobayashi, T. Natsume, M. Gondo, T. Mikami, K. Sakakibara, and S. Tsukagoshi Synthesis and antitumor activity of novel dolastatin 10 analogs Chem. Pharm. Bull. (Tokyo) 43 1995 1706 1718
13. T. Ohtsuka, M. Ota, N. Nio, and M. Motoki Comparison of substrate specificities of transglutaminases using synthetic peptides as acyl donors Biosci. Biotechnol. Biochem. 64 2000 2608 2613
14. T. Ohtsuka, A. Sawa, R. Kawabata, N. Nio, and M. Motoki Substrate specificities of microbial transglutaminase for primary amines J. Agric. Food Chem. 48 2000 6230 6233
15. P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 2009 235 244
16. P.D. Senter, and E.L. Sievers The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30 2012 631 637
17. B.Q. Shen, K. Xu, L. Liu, H. Raab, S. Bhakta, M. Kenrick, K.L. Parsons-Reponte, J. Tien, S.F. Yu, and E. Mai Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30 2012 184 189
18. Strop, P., Dorywalska, M.G., Rajpal, A., Shelton, D., Liu, S.H., Pons, J., and Dushin, R. May 2012. Engineered polypeptide conjugates and methods for making thereof using transglutaminase. WO patent 2,012,059,882.
19. L. Wang, G. Amphlett, W.A. Blattler, J.M. Lambert, and W. Zhang Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry Protein Sci. 14 2005 2436 2446
20. K. Yokoyama, N. Nio, and Y. Kikuchi Properties and applications of microbial transglutaminase Appl. Microbiol. Biotechnol. 64 2004 447 454